Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Radiopharm Theranostics.
RELATED STOCKHEAD STORIES
Explainers
ASX cancer stocks guide: Here’s everything you need to know
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
News
In Case You Missed It: Lithium does the heavy lifting today
Health & Biotech
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
Health & Biotech
ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
Health & Biotech
ASX Tech & Biotech: Kleos launches new geospatial intelligence product, Radiopharm scores FDA approval
Experts
THE SUNDAY ROAST: The ASX small caps that lit a fire under Stockhead’s experts this week.
Experts
MoneyTalks: Two reasons why today’s Aussie biotech sector is like the ’90s scramble for beachside property
Health & Biotech
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
ASX Health Stocks: Radiopharm wins US FDA Orphan status, set to accelerate treatment for rare bone cancer in kids
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Experts
